Morning Update: New guideline to treat teen obesity [Globe and Mail, The (Toronto, Canada)]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: Globe and Mail, The
More on that below, along with election campaign updates and Katy Perry in outer space. Today’s headlines Boxes of Ozempic and Wegovy made by Novo Nordisk are seen at a pharmacy in London, Britain March 8, 2024. Hollie Adams/Reuters I’m Kelly Grant, a health reporter with The Globe and Mail. Yesterday, the Canadian Medical Association Journal published the first new guideline on the treatment of childhood obesity in nearly 20 years. The headline-grabbing change is that experts now say doctors should consider prescribing weight-loss medication for children as young as 12, and weight-loss surgery for those as young as 13. The guidelines follow a major shift in the treatment of obesity with the rise of glucagon-like peptide-1 (GLP-1) receptor agonists, the class of drugs that includes semaglutide, better known as Ozempic (for diabetes) and Wegovy (for weight management.) Wegovy is approved in Canada for children 12 and up. I asked Yoni Freedhoff, a professor at the University of Ot
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- Form Health Simplifies GLP-1 Coverage Opportunities for Employers with Transparent, Predictable Pricing [Yahoo! Finance]Yahoo! Finance
- These people lost their sense of taste. Are GLP-1s to blame? [USA TODAY]USA TODAY
- Healthcare Stocks: Outlook For 2026 [Seeking Alpha]Seeking Alpha
- Lawsuits alleging GLP-1 drugs led to blindness to be centralized [Seeking Alpha]Seeking Alpha
- Update: Market Chatter: Eli Lilly Could Get FDA Decision for Weight-Loss Pill Orforglipron by March 2026 [Yahoo! Finance]Yahoo! Finance
NVO
Earnings
- 11/6/25 - Beat
NVO
Sec Filings
- 11/25/25 - Form 6-K
- 11/24/25 - Form 6-K
- 11/17/25 - Form 6-K
- NVO's page on the SEC website